Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J5EY | ISIN: US66737P6007 | Ticker-Symbol: NBYB
Stuttgart
21.11.24
08:03 Uhr
0,260 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NORTHWEST BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
NORTHWEST BIOTHERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur NORTHWEST BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.11.NORTHWEST BIOTHERAPEUTICS INC - 10-Q, Quarterly Report8
01.11.Northwest Biotherapeutics secures $5 million convertible loan3
01.11.Northwest Biotherapeutics sichert sich Wandelanleihe über 5 Millionen US-Dollar3
01.11.NORTHWEST BIOTHERAPEUTICS INC - 8-K, Current Report2
09.08.NORTHWEST BIOTHERAPEUTICS INC - 10-Q, Quarterly Report11
02.08.NORTHWEST BIOTHERAPEUTICS INC - 8-K, Current Report5
03.07.NORTHWEST BIOTHERAPEUTICS INC - 8-K, Current Report8
03.07.Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities446Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, Md., July 3, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology...
► Artikel lesen
NORTHWEST BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
17.06.Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property281Complementary to Technology & IP Already Owned or In-Licensed;Significant Step in Building a Leading Dendritic Cell Franchise BETHESDA, Md., June 17, 2024 /PRNewswire/ -- Northwest...
► Artikel lesen
04.06.NORTHWEST BIOTHERAPEUTICS INC - 8-K, Current Report6
06.02.Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification360Accompanied by Broad Patent Coverage BETHESDA, Md., Feb. 6, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized...
► Artikel lesen
21.12.23Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma490Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, Md., Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company...
► Artikel lesen
21.12.23Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastoma632Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, Md., Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1